ID | 61274 |
著者 |
Nawara, Hend M.
Laboratory of Nano‐Biotechnology, Division of Bioengineering and Drug Discovery, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
Afify, Said M.
Laboratory of Nano‐Biotechnology, Division of Bioengineering and Drug Discovery, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
ORCID
,
Laboratory of Nano‐Biotechnology, Division of Bioengineering and Drug Discovery, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
Zahra, Maram H.
Laboratory of Nano‐Biotechnology, Division of Bioengineering and Drug Discovery, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
Atallah, Marwa N.
Department of Zoology, Vertebrates Embryology, and Comparative Anatomy, Faculty of Science, Menoufia University
Seno, Akimasa
Laboratory of Nano‐Biotechnology, Division of Bioengineering and Drug Discovery, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
ORCID
Kaken ID
publons
researchmap
Seno, Masaharu
Laboratory of Nano‐Biotechnology, Division of Bioengineering and Drug Discovery, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
ORCID
Kaken ID
publons
researchmap
|
抄録 | Angiogenesis is generally involved in tumor growth and metastasis. Cancer stem cells (CSCs) are considered to facilitate the angiogenesis. Therefore, CSCs could be the effective targets to stop angiogenesis. Recently, our group successfully generated CSC models from induced pluripotent stem cells (iPSCs) in the presence of conditioned medium derived from cancer derived cells. These novel model CSCs has been characterized by highly tumorigenic, angiogenic and metastatic potentials in vivo. The angiogenic potential of CSCs has been explained by the expression of both angiogenic factors and their receptors implying the angiogenesis in autocrine manner. In this protocol we optimized the method to evaluate tumor angiogenesis with the CSC model, which was described effective to assess sorafenib as an antiangiogenic drug, on chick chorioallantoic membrane (CAM) assay. Our results demonstrate that CSCs developed from iPSCs and CAM assay are a robust and cost‐effective tool to evaluate tumor angiogenesis with CSCs. Collectively, CSCs in CAM assay could serve as a very useful model for the screening of potential therapeutic agents targeting tumor angiogenesis.
|
キーワード | cancer stem cells
chick chorioallantoic membrane
sorafenib
tumor angiogenesis
|
備考 | This fulltext is available in December, 2021.
|
発行日 | 2020-12-04
|
出版物タイトル |
Cell Biology International
|
出版者 | Wiley
|
ISSN | 1065-6995
|
NCID | AA10882014
|
資料タイプ |
学術雑誌論文
|
言語 |
English
|
OAI-PMH Set |
岡山大学
|
論文のバージョン | author
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1002/cbin.11511
|